Black Rock Inc. Biocryst Pharmaceuticals Inc Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
316Shares Held
202MCall Options Held
930KPut Options Held
553K-
Vanguard Group Inc Valley Forge, PA20.5MShares$147 Million0.0% of portfolio
-
State Street Corp Boston, MA8.51MShares$60.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.46MShares$60.5 Million9.06% of portfolio
-
Alkeon Capital Management LLC New York, NY5.71MShares$40.9 Million0.09% of portfolio
-
Ubs Group Ag5.61MShares$40.1 Million0.01% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.33B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...